ClinicalTrials.gg
RecruitingNCT05953935Updated Nov 6, 2026

Effect Of Resistive Capactive Electrical Transfer Therapy In Difficult-to-heal Wounds

An interventional study of OKTO and Standard clinical procedures in Difficult-to-heal Wounds, sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.
Updated Nov 6, 2026Now RecruitingStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
137
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Difficult-to-heal wounds present imbalances in cytokine production, increases in MMP expression, high levels of apoptosis, and decreases in the proliferation of cells such as fibroblasts and keratinocytes, which are involved in tissue regeneration. CRET therapy (capacitive resistive electrical transfer therapy) has been shown to generate granulation tissue in in vitro assays. In addition, available clinical case reports and preliminary clinical trial results indicate that CRET can promote the regeneration of acute wounds and DHW (difficult-to-heal wounds).

Read the detailed description

Difficult-to-heal wounds present imbalances in cytokine production, increases in MMP expression, high levels of apoptosis, and decreases in the proliferation of cells such as fibroblasts and keratinocytes, which are involved in tissue regeneration. CRET therapy has been shown to be able to generate granulation tissue in in vitro assays. In addition, available clinical case reports and preliminary clinical trial results indicate that CRET can promote acute wound regeneration and CDH.

The working hypothesis is that CRET treatment promotes the healing of CDH through its action in regulating inflammatory and regenerative processes in skin tissue. This non-invasive, cost-effective treatment, devoid of identified adverse effects, and not studied in depth so far in patients with CDH, can thus be placed in the treatment algorithms of CDH with the correct selection of candidate patients.

02

Conditions studied

  • Difficult-to-heal Wounds
03

In context

Lead sponsor

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal is the lead sponsor of 84 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Agree to participate in the study and sign the form.
  • Inpatients or outpatients who can be followed by the research team for the duration of the study
  • Ulcers with a surface area of no less than 0.5 cm2 and of at least 4 weeks' duration (CDH), located on the lower limbs in the case of ulcers of venous etiology or on the foot, in the case of diabetic foot ulcers.
  • For patients with ulcers of venous etiology: ulcers of venous etiology stage 2, 3 4 with diagnosis of chronic venous insufficiency with open wound CEAP IVC C6 according to CEAP classification (38).
  • For patients with diabetic foot ulcers presenting:

    • Type 1 and type 2 diabetics with a (HbA1c ≤10% (in a test no longer than 3 months).
    • Patients with UPD without PAD or with associated mild or moderate stage PAD (39) according to the criteria of the intersociety consensus for the treatment of peripheral arterial disease (TASC II).
    • UPD Grade 1A, 1C, 2A, 2C according to the Texas classification (40).
    • Patients who have required previous surgical debridement and 4 weeks have elapsed since such debridement.
  • Comorbidity is defined as the presence of at least one of the following criteria:

    • Smoking more than 10 cigarettes per day in the last 6 months.
    • : systemic treatment with high-dose in the previous 3 months, severe active infection in the previous month, presence of systemic or organ-specific disease.
    • Renal failure with creatinine > 2 mg/dl.
    • Respiratory failure with pO2\< 90 mm Hg
    • Cardiac failure, grade II or higher
    • Anemia or nutritional deficit
    • Endocrine disruption under medical treatment
    • Neuropathy in the affected area or neurological disease.
    • Connective tissue diseases
    • Mobility impairment
    • Presence of microvascular disease

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Patients with for CRET treatments (electronic implants, thrombophlebitis).
  • Patients with chronic or pathological wounds that required surgical intervention.
  • Ulcers with active infection according to IDSA classification in soft tissues or with clinical and/or radiological signs compatible with osteomyelitis.
  • Allergies to standard wound treatment.
  • Patients presenting severe renal insufficiency ( ≤30 ml/min in analysis performed in the last 3 months).
  • Patient who has presented an acute ischemic event (acute myocardial infarction or stroke, in the 3 months prior to inclusion in the study).
  • Patients who present an evolving neoplastic condition, treated by radiotherapy, chemotherapy, hormone therapy or at the current moment.
  • Patients treated for a chronic condition requiring the intake of strong systemic doses ≥ 40 mg prednisone).
  • Critical non-revascularizable ischemia or TcPO2 \< 25mmHg or a digital hallux systolic pressure \< 50 mm Hg in diabetic foot ulcers.
  • Patients who do not accept to use the prescribed unloading treatment in the case of diabetic foot ulcers.
  • In the case of patients with ulcers of venous etiology, the presence of peripheral arterial disease in any of its stages.
  • Patients who do not accept the indicated compressive bandage treatment, in the case of ulcers of venous etiology.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
137 participants (estimated)

Study arms

  • Experimental
    A-E group

    Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments, in patients with ulcers of venous etiology.

    Device: OKTO · Device: Standard clinical procedures

  • Experimental
    B-E group

    Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments in patients with diabetic foot ulcers.

    Device: OKTO · Device: Standard clinical procedures

  • Experimental
    A-C grouop

    Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments in CDH.

    Device: OKTO · Device: Standard clinical procedures

  • Experimental
    B-C grouop

    Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under subthermal conditions plus standard clinical treatments in CDH.

    Device: OKTO · Device: Standard clinical procedures

  • Experimental
    C-C group

    Standard clinical treatments established on the basis of the treatment standards of the International Working Group on the Diabetic Foot (IWGDF), in the case of diabetic foot ulcers (2, 3). For ulcers of venous etiology, the treatment standards according to the guidelines of the Spanish Association of Vascular Nursing and Wounds (Asociación Española de Enfermería Vascular y Heridas) will also be applied.

    Device: Standard clinical procedures

Interventions

  • DeviceOKTO

    Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz

  • DeviceStandard clinical procedures

    standard clinical procedures

06

What researchers measure

Primary outcomes

  1. Wound dimensions before and after treatments in patients with HDC treated with CRET therapy plus standard treatment versus patients with HDC undergoing standard treatment alone.

    Wound dimensions measurement (area, length and width) before and after treatments in patients with HDC treated with CRET therapy plus standard treatment versus patients with HDC undergoing standard treatment alone.

    Time frame: 18 months

Secondary outcomes

  1. General clinical evaluation:

    * age, * sex, * BMI * general medical history, * baseline blood work, * usual treatment

    Time frame: 18 months

  2. Wound evaluation:

    * cause, * location, * time of evolution, * photographs.

    Time frame: 18 months

  3. Evaluation of biomarkers in peripheral blood of patients with CDH with or without CRET treatment:

    Quantification of cytokines and growth factors: IL-1α, IL-1β, TNFα, IFγ.

    Time frame: 18 months

  4. In primary cultures of fibroblasts isolated from biopsies of CDH patients with or without CRET treatment, assessment of typical CDH biomarkers related to:

    * Death: TUNEL assay; Bcl-2, Bcl-X and Caspase-3 markers. * Viability/proliferation: XTT, Ki67, p-p38 and p-ERK1/2 assays. * Adhesion: β -catenin and E-cadherin. * Extracellular matrix: α-SMA, Col I and Col III and the metalloproteinases, MMP8, MMP2 and MMP9.

    Time frame: 18 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2024 to primary completion in Jul 2024, 6 months.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2025 → Jun 2027, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2023
First posted
Jul 20, 2023
StartActual
Jan 31, 2024
Primary completionActual
Jul 31, 2024
CompletionEst.
Jun 2027was Jun 2025
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 6, 2026
Sites
1 site added, 1 site removed
Show site
  • Hospital Ramón y Cajal · Madrid, Spain
Show 1 removed
  • Hospital Ramón y Cajal · Madrid, Spain
Nov 6, 2026
Study completion
Jun 2025→Jun 2027
Nov 6, 2026
Contact
Study contact now listed: added m•••@hrc.es · •••8699; added a•••@salud.madrid.org. See the current contact
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Active, not recruiting→Recruiting
    1 site added, 1 site removed
    Show site
    • Hospital Ramón y Cajal · Madrid, Spain
    Show 1 removed
    • Hospital Ramón y Cajal · Madrid, Spain
    Study completion Jun 2025→Jun 2027
    Contact Study contact now listed: added m•••@hrc.es · •••8699; added a•••@salud.madrid.org. See the current contact
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05953935
Lead sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Responsible party
Sponsor
First posted
Jul 20, 2023
Start date
Jan 31, 2024
Primary completion
Jul 31, 2024
Completion
Jun 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Maria Luisa Hernández Bule, PhD
Contact
mluisa.hernandez@hrc.es
913368699
Almudena Cecilia Matilla
Contact
almudena.cecilia@salud.madrid.org
Maria Luisa Hernández Bule, PhD
principal investigator · IRYCIS. Hospital Universitario Ramón y Cajal. Madrid, Spain.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion